肾细胞癌免疫相关病理缓解标准的可行性与特征分析
该回顾性队列纳入35例患者(37个肿瘤),评估国际新辅助肾癌联盟推荐的免疫相关病理缓解标准(irPRC)在肾细胞癌中的可行性。irPRC在所有病例中均可实施,35%的肿瘤达到主要病理缓解,瘤床评估显示显著异质性。影像学缓解与病理发现相关性差,近三分之一主要病理缓解者缺乏显著影像学改善。
要点
- irPRC在肾细胞癌系统治疗后病理评估中可行,35%肿瘤达主要病理缓解。
- 基于irPRC组分的瘤床评估显示显著异质性,仅依赖肿瘤比例有局限。
- 影像学缓解与病理缓解相关性差,近三分之一主要病理缓解者无显著影像改善。
核心结论
- irPRC在肾细胞癌中可行,并揭示当前影像学和传统病理缓解评估的局限性。
研究设计与样本
- 回顾性队列研究,纳入35例患者共37个肿瘤,评估irPRC的可行性与实施情况。
主要发现
- irPRC在所有病例中均可实施,35%的肿瘤达到主要病理缓解。
- 基于irPRC组分的瘤床评估显示显著异质性,凸显仅依赖肿瘤比例的局限性。
- 术后6个月内复发的全部11例患者均表现为坏死为主的瘤床且完全缺乏组织修复特征。
- 影像学缓解与病理发现相关性差,近三分之一主要病理缓解者缺乏显著影像学改善。
关键数值与推荐
- 主要病理缓解定义为irPRC评估结果,发生于35%的肿瘤。
- 术后6个月内复发患者(N=11)均显示坏死为主瘤床且无组织修复特征。
临床怎么用
- 采用标准化irPRC框架可能提高肾细胞癌病理缓解报告的一致性。
- 临床研究中应结合irPRC评估,不应仅依赖影像学或传统病理缓解指标。
局限性
- 回顾性设计且样本量较小(35例患者,37个肿瘤)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pathologic assessment of treatment response in renal cell carcinoma (RCC) after systemic combination therapy is increasingly relevant, yet traditional reporting methods fail to capture unique immune-mediated changes, and a lack of standardized reporting recommendations has led to discordant clinical trial definitions. We evaluated the feasibility and implementation of immune-related pathologic response criteria (irPRC), recently endorsed by the International Neoadjuvant Kidney Cancer Consortium, in a retrospective cohort of 35 patients (37 tumors). Application of irPRC was feasible in all cases and identified major pathologic response in 35% of the tumors. Tumor bed evaluation based on irPRC components revealed substantial heterogeneity, highlighting the limitations of relying on tumor fraction alone. All patients (N = 11) experiencing recurrence within 6 mo of surgery exhibited necrosis-predominant tumor beds and a complete absence of tissue repair features, suggesting an area for additional research. In addition, radiographic response correlated poorly with pathologic findings; nearly one-third of major pathologic responders lacked significant radiographic improvement. These findings support the feasibility of irPRC in RCC and underscore the limitations of current radiographic and traditional pathologic response assessments. Broader adoption of standardized immune-related pathologic response frameworks may improve consistency in reporting and better reflect underlying tumor biology in clinical research.
引用
- Croll BJ, Yahya HA, Fredette J, et al. Feasibility and Characterization of Immune-related Pathologic Response Criteria in Renal Cell Carcinoma. Eur Urol Oncol. 2026. PMID: 42728152. doi:10.1016/j.euo.2026.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。